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Abstract
Background: Adrenomedullin (AM) is highly expressed in pancreatic cancer and stimulates pancreatic cancer cells leading
to increased tumor growth and metastasis. The current study examines the role of specific AM receptors on tumor and cells
resembling the tumor microenvironment (human pancreatic stellate - HPSC, human umbilical vein – HUVEC and mouse
lung endothelial cells - MLEC).
Methods and Findings: AM receptors ADMR and CRLR were present in HPSC, HUVEC and MLECs while PDAC cells
possessed only ADMR receptors as assessed by RT-PCR and western blotting. All cell lines expressed and secreted AM as
indicated by ELISA. The growth of each of the cell lines was stimulated by exogenous AM and inhibited by the antagonist
AMA. AM also stimulated in vitro angiogenesis assessed by polygon formation of endothelial cell lines. SiRNA-mediated
silencing of ADMR, but not CRLR, reduced basal growth of all cells examined and reduced polygon formation of endothelial
cells in vitro. Orthotopic tumors developed with shADMR bearing cancer cells had dramatically reduced primary tumor
volume (.90%) and lung and liver metastasis compared to shControl bearing cells. To validate ADMR as a potential
therapeutic target, in vivo studies were conducted using neutral nanoliposomes to systemically deliver human siRNA to
ADMR to silence human cancer cells and mouse siRNA to ADMR to silence mouse tumor stromal cells. Systemic silencing of
both human and mouse ADMR had no obvious adverse effects but strongly reduced tumor development.
Conclusion: ADMR mediates the stimulatory effects of AM on cancer cells and on endothelial and stellate cells within the
tumor microenvironment. These data support the further development of ADMR as a useful target treatment of pancreatic
cancer.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related
death in the United States and it has been estimated that in 2008
approximately 37,680 Americans were diagnosed and 34,290
died from this disease [1]. Although significant advances are
beginning to be made into the management of the disease, the 5-
year survival rate has not improved over the past 25 years [1].
The high mortality rate is due to the high incidence of metastatic
disease at initial diagnosis, the aggressive clinical course and the
failure of systemic therapies [2]. Therefore, there is an urgent
need for improved understanding of the molecular biology of the
disease that can be utilized to develop new therapies for
pancreatic cancer.
We previously showed that adrenomedullin (AM) is over-
expressed in pancreatic cancer and has a strong autocrine role in
this disease [3]. AM is a 52 amino acid peptide originally isolated
from human pheochromocytoma [4] that acts as a multifunctional
regulatory peptide [5]. One issue with AM as a target for cancer
therapy is that AM has several physiological functions whose
inhibition may be detrimental. AM is expressed in normal
pancreatic islet cells, with predominant expression in the F cells,
which also contain pancreatic polypeptide [6]. AM reduces insulin
secretion in physiological conditions [6]. AM also has important
effects in vascular cell biology where it regulates vascular tone and
permeability and promotes vasodilation [7–11]. AM is also a
potent angiogenic molecule, especially in hypoxia, which induces
AM [10]. The angiogenic effects of AM are likely mediated
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protection of endothelial cells from apoptosis [13]. Adrenome-
dullin signaling is necessary for murine lymphatic vascular
development [14]. Mice in which AM has been genetically deleted
develop cutaneous edema and midgestational lethality due to
defect in lymphatic vessel growth and cardiovascular defect [15].
In cancer, AM appears to have an important role in angiogenesis
as well as an additional trophic effect directly on cancer cells
[16–18].
AM acts as a peptide ligand that activates receptors on the cell
surface. Pancreatic beta cells express receptors known to respond
to AM including the adrenomedullin receptor (ADMR, also
known as L1-R) and the calcitonin-receptor-like-receptor (CRLR)
[6,19,20]. Our previous study found that pancreatic cancer cells
express only ADMR, while both receptors are present in cells
found within the tumor microenvironment including human
pancreatic stellate cells (HPSCs) and endothelial cells. However,
the roles of the specific receptors in AM’s effects on pancreatic
cancer, HPSCs and endothelial cells are currently unknown.
The current study examines the effects of AM on human
pancreatic tumor cells, HPSCs and endothelial cells and
investigates the receptors involved in these effects. We silenced
each of the receptors in vitro using siRNA and found that ADMR
was primarily responsible for the biological effects of AM on each
of these cell types. We then examined the effects of silencing
ADMR on pancreatic cancer cells and observed a major reduction
of tumor growth in vivo. To analyze the potential of ADMR as a
target of cancer therapy, we then evaluated the effects of silencing
ADMR in both mouse cells that make up the tumor microenvi-
ronment and on human cancer cells by using DOPC nanolipo-
somes to deliver species specific siRNAs. This systemic silencing of
ADMR did not have obvious deleterious effects on healthy mice
but greatly reduced tumor development. Therefore, ADMR
should be an important target for the future development of small
molecule therapeutics.
Materials and Methods
Cell Lines and AM Peptides
Pancreatic cancer BxPC3 cells and HUVEC cell lines were
obtained from the American Type Culture Collection (Manassas,
VA). MPanc96 pancreatic adenocarcinoma cell lines were
originally established by Dr. Timothy J. Eberlein (St. Louis,
MO) [21]. MLECs are microvascular endothelial cells from
primary cultures obtained from lungs of mice whose tissues harbor
a temperature-sensitive SV40 large T antigen [22]. When cultured
under permissive temperatures (33uC), cell lines displayed
doubling times consistent with endothelial cells possessing an
angiogenic phenotype. The transfer of these endothelial cells to
non-permissive temperatures (37uC) resulted in cell differentiation
and the induction of a quiescent state. MLECs were cultured in
10% FBS in DMEM. BxPC3 cells were cultured in 10% FBS in
RPMI media, MPanc96 cells were cultured in 10% FBS in
DMEM media and human endothelial cells (HUVEC) were
cultured in 15% FBS in MEM. All media contained 1% antibiotic.
Human pancreatic stellate cells (HPSCs) were isolated using the
outgrowth method from pancreatic adenocarcinoma samples from
patients undergoing surgical resection and cultured in 15% FBS in
DMEM [3,23]. All cells were maintained at 37uC in a humidified
atmosphere of 5% CO2. BxPC3 and MPanc96 cell lines stably
bearing shControl or shADMR vectors and the luciferase gene
developed in an earlier study were also used [3]. Adrenomedullin
(AM 52) and adrenomedullin antagonist (AMA (AM 22–52)) were
purchased from Sigma, (St. Louis, MO).
ELISA for AM
AM was detected in conditioned media from HPSC, HUVEC
and MLECs using a commercial ELISA. For collection of
conditioned media, cell lines were grown to 80% confluence and
washed with PBS and then cultured for 24 hrs in their respective
serum-free media. Media was collected and concentrated using
Centricon YM-3 filter devices (Millipore Corporation, Chicago,
IL). Protein concentrations were determined using Bio-Rad
reagent (Bio-Rad Laboratories, Hercules, CA). Competitive
ELISA was then conducted using an AM detection kit (Phoenix
Pharmaceuticals, Belmont, CA; cat # EK-010-01) following the
manufacturer’s suggested protocol. Respective concentrated
serum-free media served as reagent control and control OD
values were subtracted from those of all other samples.
Calculations of AM concentration utilized the standard curve
included in the kit and were conducted according to the
manufacturer’s protocol.
Transient transfection of siRNA
Silencing of ADMR and CRLR was achieved in HPSC,
HUVEC and MLECs (2610
4 cells) using transient transfection of
siRNAs. Human and mouse siRNAs each against control, ADMR
and CRLR (siRNAs ID # 4611, 46184, 42272, Ambion Inc.
Austin, TX and custom made mouse siRNAs ID # Control -
1129089, 1129090; ADMR - 1129085, 1129086; CRLR -
1129087, 1129088 from Sigma-Aldrich (Proligo), St.Louis, MO)
were transfected at a final concentration of 5 nM per well on 96-
well plates. We also analyzed the effects of siADMR on MPanc96
cancer cells. SiRNA transfection was carried out with Hiperfect
transfection reagent (Qiagen, Valencia, CA) as per the manufac-
turer’s protocol.
Western Blotting
MPanc96, HPSC, HUVEC and MLEC cells were transiently
transfected with control siRNA or siRNAs against ADMR or
CRLR and after 72 hours, cell lysates were prepared and protein
concentrations were measured by BioRad reagent. Protein (50 mg)
was loaded onto 10% SDS-PAGE gels and western blotting was
conducted using a primary antibody against ADMR (cat # LS-
A4048 MBL International Corporation, Woburn, MA) at a 1:
1000 dilution and using a primary antibody against CRLR (cat #
sc-30028, Santa Cruz Biotechnology, Santa Cruz, CA) at a 1: 100
dilution. The same blot was re-probed for b-Actin (1:200 dilution;
cat # A2066 Sigma, St.Louis, MO), which served as loading
control.
RT-PCR
Total RNA was extracted from HPSC, HUVEC and MLEC
cells with or without siRNA transfection and from mouse
pancreas. DNase was used to remove contaminating genomic
DNA after RNA purification. The integrity of the RNA was
confirmed by running on a denaturing gel, and observing clear
28S and 18S rRNA bands. A non-reverse transcribed control was
run to assure that no genomic DNA was amplified. RT-PCR was
conducted with human and mouse AM/ADMR/CRLR primers
to determine their expression and levels of silencing. Reverse
transcription was followed by 35 cycles of standard PCR (1-min
denaturation at 94uC, 1-min annealing at 63uC, and 1-min
extension at 72uC). Primers designed for human AM (Genebank:
NM_001124) were: forward 59CGG GAT CCA TGA AGC TGG
TTT CCG TC 39 and reverse, 59 CGG AAT TCC TAA AGA
AAG TGG GGA GC 39. Primers designed for human ADMR
(Genebank: NM_007264) were: forward 59 CAT CGC GGA
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GCA GCA GGA AGC 39. Primers designed for human CRLR
(Genebank: NM_005795) were: forward 59TGC TCT GTG AAG
GCA TTT AC 39 and reverse, 59 CAG AAT TGC TTG AAC
CTC TC 39. Primers designed for mouse AM (Genebank:
NM_009627) were:forward 59 CCA GGG TTC CCG CAG
CAA 39 and reverse, 59 CTA TAT CCT AAA GAG TCT GG 39.
Primers designed for mouse ADMR (Genebank: NM_007412)
were: forward 59 CCG TTA CCT TCC CAA GGA 39 and
reverse, 59 TTA GCT GGC TAC AGA ATT GCA 39. Primers
designed for mouse CRLR (Genebank: NM_018782) were:
forward 59 TGG CTT TTC CCA CTC TGA T 39 and reverse,
59 TCA CAT CAC TAG ATC ATA CGT 39. 18S primers served
as loading control for the RT-PCR reactions. Amplified products
were separated on 1.5% agarose gels and visualized by ethidium
bromide.
Cell growth studies
HPSC, HUVEC and MLECs (1000 cells) were plated on 96-
well plates in 0.5% serum containing media with or without AM
(0–200 nM) or AMA (1 mM), which were refreshed daily, and cell
numbers were estimated after 48 hours for HPSC and HUVEC
cells and after 96 hours for MLECs by MTS assay. For siRNA
studies, HPSC, HUVEC and MLECs (1000 cells) were plated on
96-well plates and respective human and mouse siControl/
siADMR/siCRLR were transfected and cell numbers were
estimated after 48 hours for HPSC and HUVEC cells and after
96 hours for MLECs. Cell growth was analyzed using the MTS
reagent added one hour before taking the spectrophotometric
reading according to the manufacturer’s directions (Promega,
Madison, WI).
In vitro Angiogenesis assay
HUVEC and MLEC (1610
4) cells were seeded onto the surface
of the polymerized ECMatrix prepared as described by the
manufacturer (Cat # ECM625; Chemicon Intl, Millipore Corp,
Billerica, MA). Cells were treated with AM (200 nM) or AMA
(1 uM) peptides and after 6 hours tube formation was evaluated
under an inverted light microscope (Olympus, Center Valley, PA).
Images were captured using a chilled, charge-coupled device
camera (Hamamatsu, Bridgewater, NJ) and SmartCapture
software (Digital Scientific, Cambridge, UK). Images were further
processed with Adobe Photoshop software (Adobe Systems,
Mountain View, CA). To quantify the angiogenic events, the
patterns of cell growth in 10 random fields at 1006magnification
was assessed as per the manufacturer’s suggestions and graded as:
Individual cells, well separated –0; Cells migrated and aligned –1;
Capillary tubes visible, no sprouting –2; Sprouting of capillary
tubes –3; Closed polygons formed – 4; and complex mesh-like
structures developed –5.
Immunohistochemical staining - CD31/VEGF
Unstained 4 mm tissue sections from siControl or siADMR
treated mice were deparaffinized with xylene and rehydrated with
ethanol. Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in methanol and non-specific binding sites
were blocked with protein blocking solution (5% normal horse and
1% normal goat serum). Primary antibody against CD31 (1: 800
dilution; cat # 01951A; BD Pharmingen, San Diego CA)/VEGF
(1:100 dilution; cat # sc-152; Santa Cruz Biotechnology, Santa
Cruz, CA) was added and samples were incubated overnight at
4uC. Secondary antibody was added and incubated for 1 hour at
room temperature. Finally, slides were developed with 3,3-
diaminobenzidine (DAB) substrate counterstained with hematox-
ylin, dehydrated with ethanol, fixed with xylene and mounted.
Immunohistochemistry was analyzed using an inverted light
microscope (Olympus, Center Valley, PA). Images were captured
using a chilled, charge-coupled device camera (Hamamatsu,
Bridgewater, NJ) and SmartCapture software (Digital Scientific,
Cambridge, UK). Images were further processed with Adobe
Photoshop software (Adobe Systems, Mountain View, CA). Slides
were blinded and analyzed by IHC core in Dept. of Cancer
Biology, UT MDACC.
DOPC nanoliposome coupled siRNAs. For experiments to
test the efficacy of in vivo therapeutic targeting of ADMR in orthotopic
tumors in mice, neutral liposomes containing siRNAs were prepared as
previously described [24]. Briefly, siRNA oligonucleotides (without
hairpins) to ADMR target sequences (human siADMR (sense - 59
rGrCUrGrCUUrGrArCrCUrCUUrCrArArCTT 39); mouse siRNA
sense sequence – 59 rCrCUUUUrGrArArArCrGUrArCrArGrCr-
GTT 39) or control sequences (control siRNA sense sequence – 59
UUrCUrCrCrGrArArCrGUrGUrCrArCrGUTT 39)( c u s t o mm a d e
human and mouse oligos cat # HumansiADMR - 1150080,1150081;
Mouse siADMR - 1129085-H, 1129086-H; Control - 1129089,
1129090 from Sigma-Aldrich (Proligo), St.Louis, MO) were mixed
with 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) (Avanti
Polar Lipids, Alabaster, AL) at a ratio of 10:1 (w/w) DOPC/siRNA
and lyophilized. Immediately before in vivo administration, lyophilized
preparations were hydrated in 0.9% saline at a concentration of 10 mg
of siRNA per 200 ml and were purified by separating free siRNA from
liposomes with filter units with a size exclusion limit of 30,000 Daltons
(Millipore Corp, Billerica, MA).
Glucose Tolerance Test. For glucose tolerance, mice were
injected intraperitoneally with 1.5 mg of glucose/g body weight at
9:00 a.m., after a 16-h fast. Blood glucose was determined at the
indicated times with samples of tail blood obtained using the
Ascensia CONTOUR Blood glucometer (Bayer Health Care,
Tarry town, NY).
In vivo studies. All animals were handled in strict
accordance with good animal practice as defined by the relevant
national and/or local animal welfare bodies, and all animal work
was approved by the appropriate committee (IACUC - 09-04-
08832). Orthotopic tumor model. MPanc96 and BxPC3 cells
bearing shADMR or shControl were developed as mentioned in a
previous publication [3]. These pancreatic cancer cells were
further modified to stably express the firefly luciferase gene by
lentivirus transfection to facilitate in vivo monitoring of tumor
development [25]. These cells were grown to 80% confluence,
harvested by trypsinization, washed twice in PBS, and
resuspended to a final concentration of 1610
6 cells/50 ul of
MPanc96 cells and 2610
6 cells/50 ul of BxPC3 cells in sterile PBS
and injected into the pancreas of four-week old male athymic nude
mice (n=5). Tumor growth was assessed by bioluminescence
imaging at the end of four weeks. Lung and liver metastasis
models. Comparisons were made between lung and liver
metastasis in MPanc96 cells bearing shADMR or shControl cells
using well established metastasis models. Lung metastases were
developed by tail vein injection of 1610
6 cells/100 ul (n=9) and
liver metastases by splenic injection of 1610
6 cells/50 ul (n=7) to
athymic nude mice and evaluated by bioluminescence imaging. After
six weeks, mice were sacrificed and organs were excised and stored
in Bouin’s fixative solution. Delivery of DOPC nanoliposome
coupled siRNAs. For evaluation of potential toxicity,
experiments were conducted delivering DOPC nanoliposome
coupled siControl or siADMR (mouse) to athymic nude mice (10 ug
per animal i.p. twice a week for four weeks). Water and food
intake, body weight and blood glucose levels were measured.
Animals were sacrificed after four weeks, the pancreas was isolated
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silencing of ADMR, while 18S served as internal control.
Orthotopic tumors were developed in athymic nude mice with
MPanc96 cells bearing the luciferase gene (1610
6 cells/50 ul of
sterile PBS) and two weeks later, DOPC nanoliposome coupled
siControl and siADMRs (human and mouse in combination) were
delivered 10 ug per animal i.p. twice a week for six weeks.
Bioluminescence imaging. Bioluminescence imaging was
conducted using a cryogenically cooled imaging system coupled
to a data acquisition computer running LivingImage software
(Xenogen Corp., Alameda, CA). Before imaging, animals were
anesthetized in an acrylic chamber with 1.5% isofluorane/air
mixture and injected i.p. with 40 mg/ml of luciferin potassium salt
in PBS at a dose of 150 mg/kg body weight. A digital grayscale
animal image was acquired followed by acquisition and overlay of
a pseudocolor image representing the spatial distribution of
detected photons emerging from active luciferase within the
animal. Signal intensity was quantified as the sum of all detected
photons within the region of interest per second. After the final
tumor imaging, the tissues were removed and the animals were re-
imaged to visualize and count cancer cell dissemination and
metastases. Tissues were also fixed with formaldehyde and
histology was evaluated to verify the accuracy of the
bioluminescence data.
Statistical Analysis
All in vitro experiments were conducted in triplicate and carried
out on three or more separate occasions. Data presented are
means of the three or more independent experiments6Standard
Error of the Mean (SEM). Statistically significant differences
between controls and treated samples were determined by two-
tailed unpaired Student’s T-test and were defined as *p,0.05.
Results were compared using GraphPad Prism 4 software
(GraphPad Software, http://www.graphpad.com).
Results
AM has autocrine effects on HPSC, HUVEC and MLEC cells
Previously we observed that AM served as an autocrine
regulator of proliferation, survival, and motility of pancreatic
cancer cells [3]. To determine whether AM also influenced
H P S C ,H U V E Ca n dM L E C s ,w ef i r s te x a m i n e dw h e t h e rt h e y
expressed AM and its receptors ADMR and CRLR as measured
by RT-PCR. All three cell lines expressed AM, ADMR and
C R L R( F i g .1 A ) .F u r t h e r ,w ea s s e s s e dw h e t h e rt h e s ec e l l s
secreted AM into tissue culture media using an ELISA. All these
cell types secreted AM (Fig. 1B), supporting the role of this
molecule as an autocrine regulator in multiple cell types. To
examine the effects of AM on the biology of these cells,
exogenous AM was added to HPSC (Fig. 1C), HUVEC (Fig. 1D)
and MLEC (Fig. 1E) cells and proliferation was assessed by the
MTS assay. Previous studies indicated that the optimal
concentration of AM was 50 nM for HPSC and 200 nM for
HUVEC and MLEC cells (data not shown). Addition of AM at
the optimal concentrations stimulated the growth of HPSCs by
2961.8% (p,0.05), HUVECs by 2563.7% (p,0.05) and
MLECs by 3364.5% (p,0.05). Furthermore, addition of the
AM antagonist, AMA (1 uM), reduced the basal growth of
HPSCs by 2165.3% (p,0.05), HUVECs by 2160.4% (p,0.05)
and MLECs by 2565.1% (p,0.05) further supporting an
autocrine role of AM on these cells. To further examine the
effects of AM and we conducted in vitro angiogenesis assays. AM
stimulated polygon formation in HUVECs (Fig. 1F) and in
MLECs (Fig. 1G) at 6 hours compared to control cultures, and
AMA blocked the AM mediated effects of polygon formation.
The effects of AM on HPSC, HUVEC and MLEC cells are
mediated via the ADMR receptor
There are two potential receptors that respond to AM,
ADMR and CRLR. We previously reported that human
pancreatic cancer cells express exclusively ADMR while HPSC
a n dH U V E Cc e l l se x p r e s s e db o t hA Mr e c e p t o r s[ 3 ] .I nt h e
current study, we observed that MLECs also express both
receptors. To determine the relative importance of these
receptors we silenced them independently on these three cell
lines using siRNA techniques. Transfection with siRNA
significantly reduced the levels of either ADMR or CRLR on
HPSC (Fig. 2A), HUVEC (Fig. 2B) and MLECs (Fig. 2C) as
compared to control siRNAs. HPSC, HUVEC and MLECs
silenced with siRNA for either ADMR or CRLR were examined
in growth assays where cell numbers were estimated using the
MTS method. Silencing of ADMR, but not CRLR, significantly
reduced the growth of all of these cell types. Silencing of ADMR
reduced the growth of HPSC by 2163.4% (p,0.05) (Fig. 2D),
HUVECs by 2461.8% (p,0.05) (Fig. 2E) and MLECs by
2664.3% (p,0.05) (Fig. 2F). Silencing of ADMR on HUVECs
(Fig. 2G) and MLECs (Fig. 2H) completely abolished AM
mediated tube formation, while silencing of CRLR partially
reduced tube formation. These data collectively suggest that the
autocrine effects of AM on HPSC, HUVEC and MLEC cells are
mediated primarily via the receptor ADMR although CRLR
m a ya l s oh a v es o m ee f f e c t s .
Silencing of ADMR on pancreatic cancer cells reduced
tumor growth and metastasis in vivo
To examine the effects of ADMR silencing on cancer cells, we
observed the growth of orthotopic tumors formed from two
different pancreatic cancer cell lines transfected with either
shADMR or shControl. Tumor volumes were measured after 4
weeks by bioluminescence imaging. The tumor volume was
reduced by 9260.5% in ADMR silenced MPanc96 tumors when
compared to control vector bearing tumors (p,0.05) (Fig. 3A).
Likewise, BxPC3 tumor volume was significantly reduced by
8360.6% after ADMR silencing compared to control tumors
(p,0.05) (Fig. 3B). In both cases, there was also a reduction in lung
and liver metastasis and a reduction in peritoneal dissemination.
However, because ADMR silencing reduced the tumor volume;
any reduction in metastasis may have been due to the general
reduction in tumor volume.
Silencing of ADMR on pancreatic cancer cells reduced
metastasis in vivo
To directly evaluate the role of ADMR in pancreatic cancer
lung and liver metastasis, we conducted separate studies in nude
mice by tail vein and splenic injection, respectively. ADMR
silencing reduced the incidence of lung metastasis (ShControl -
67% Vs ShADMR – 22%) as measured by bioluminescence
imaging (Fig. 4A). Furthermore, the presence of metastasis
detectable using bioluminescence imaging was postponed from
the 2
nd week in control animals to 5
th week in shADMR bearing
cells. Excised lungs after fixation in Bouin’s solution showed
reduction in the number of lung metastatic foci as shown in the
representative image (Fig. 4C). The effects of ADMR silencing on
liver metastasis were similar to those on lung metastasis. ADMR
silencing reduced the incidence of liver metastasis (ShControl -
100% Vs ShADMR – 43%) (Fig. 4B). The presence of detectable
ADMR Role in Pancreatic Cancer
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7502Figure 1. Autocrine effects of AM on HPSC and endothelial cells. (A) RT-PCR showing the expression of AM, ADMR, and CRLR on HPSC, HUVEC
and MLECs. (B) ELISA assay showing the secretion of AM from HPSC, HUVEC and MLEC cells. Serum-free media bathing these cells were collected and
concentrated andassayedfor the presence of AM. Levelswere calculated as permanufacturer’sinstruction. (C) HPSC, (D) HUVEC,or (E) MLEC cells (1000
cells) were plated on 96-well plates and AM (50 nM for HPSC and 200 nM for HUVEC and MLEC) or AMA (1 uM) were added to the plates daily and cell
numbers were estimatedafter 48 hours for HPSC andHUVECcells andafter96 hoursfor MLECsby MTS assay. Whencomparedto the WT control group,
AM stimulated the proliferationof allthree cell types.Likewise, AMA treatmentinhibitedbasal proliferation of all of the cells.Data shown aremeans +/2
SEM (*p,0.05). In vitro angiogenesis assays were conducted with (F) HUVEC and (G) MLEC cells. Cells were plated on EC matrix along with AM (200 nM)
alone or in combination with AMA (1 uM). After 6 hours tube formation was evaluated microscopically as per manufacturer’s instruction. Shown are
representative micrographs. AM consistently stimulated HUVEC and MLEC cells to form tubes, while AMA reversed the effects of AM.
doi:10.1371/journal.pone.0007502.g001
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7502Figure 2. Autocrine effects of AM on HPSC and endothelial cells are mediated via ADMR but not CRLR. (A) HPSC and (B) HUVEC cells
were transiently transfected with human siRNAs and (C) MLEC cells were transfected with mouse siRNAs (siControl, siADMR, or siCRLR). After 72 hours
cells were harvested and protein or RNA was extracted. Western blotting using human antibodies shows the extent of silencing of human ADMR and
CRLR in HPSC and HUVEC cells, and RT-PCR using mouse primers shows the effects of mouse siADMR and siCRLR on MLECs. b-Actin served as a
loading control for western blotting and 18S primers served as a loading control for RT-PCR. Full length gels are presented in Figure S1. The effects on
proliferation of siRNA mediated silencing of receptors are shown on (D) HPSC, (E) HUVEC, and (F) MLEC cells. Cells were transfected with their
respective human or mouse siRNAs (siControl, siADMR, or siCRLR) for 24 hours then proliferation was estimated by MTS assay after an additional
48 hours for HPSC and HUVEC cells and 96 hours for MLECs. Silencing of ADMR but not CRLR caused a significant reduction of the proliferation of
these cells. Data shown are means +/2 SEM (*p,0.05). In vitro angiogenesis assay with (G) HUVEC and (H) MLEC cells. Cells were plated on matrix gel
24 hours after transfection with their respective human or mouse siRNAs (siControl, siADMR, or siCRLR). Cells were then treated with AM (200 nM) for
6 hours and examined microscopically. The extent of tube formation was evaluated as per the manufacturer’s instruction. Representative
micrographs are shown. ADMR silencing completely blocked tube formation, while CRLR silencing only partially reduced tube formation.
doi:10.1371/journal.pone.0007502.g002
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th week.
Reduction in the number of liver metastatic foci is shown as a
representative image (Fig. 4D). These data indicate that AM can
act as a metastasis inducer of pancreatic cancer cells and these
effects of AM on cancer cells are mediated via the receptor
ADMR.
In vivo targeting of ADMR using systemic delivery of
siRNAs is highly effective at reducing tumor growth
Our data support a role for ADMR in the effects of AM on
pancreatic cancer cells. However, AM has physiologic functions
such that inhibition of one of its receptors might cause harmful
effects on overall health. To analyze the effects of targeting these
receptors systemically in vivo, we silenced ADMR on both human
cancer cells and on mouse tissue using in vivo delivery of siRNA in
DOPC nanoliposomes. We first examined the efficiency of using
targeted siRNAs to reduce ADMR levels in human pancreatic
cancer cells by western blot analysis of ADMR levels in MPanc96
cells. Transient transfection of siADMR completely silenced the
ADMR expression in MPanc96 cells (Fig. 5A). Silencing of
ADMR did not influence the cellular levels of AM as measured by
ELISA (data not shown). Therefore, this siRNA was highly
effective at silencing ADMR expression in human cells. However,
these siRNAs had no effect on ADMR expression in NIH3T3
mouse cells (data not shown).
To silence ADMR in the mouse, we developed DOPC
nanoliposome coupled siControl and siADMR (mouse specific).
We examined the effectiveness and the potential toxicity of
delivering these siRNA (10 ug per animal i.p. twice a week for four
weeks). We observed that delivery of DOPC nanoliposome
coupled mouse siADMR for a period of four weeks led to a
complete silencing of ADMR in the pancreas as analyzed by RT-
PCR (Fig. 5B). In contrast, there was no decrease in ADMR
expression in animals treated with DOPC nanoliposome coupled
siControl. Importantly, silencing of ADMR in the mouse by i.p.
delivery of DOPC nanoliposomes did not have any noticeable
effect on the body weight (Fig. 5C), water intake or physical
activity of the mice. Since AM is said to have inhibitory effects on
insulin secretion [6], blood glucose levels were measured to see if
any changes occurs on systemic silencing of ADMR in mouse.
GTT showed no changes on DOPC nanoliposome coupled mouse
siADMR injected animals when compared to DOPC nanolipo-
some coupled siControl animals (Fig. 5D). These observations
suggest that silencing of ADMR, at least for four weeks, was not
toxic or overtly deleterious.
Next we examined the effectiveness of delivering a combination
of DOPC nanoliposome coupled siRNAs against human and
mouse ADMR to simulate systemic therapies that might be
utilized in humans. The DOPC nanoliposome coupled siRNAs
were delivered to animals with orthotopic tumors formed from
human MPanc96 cells and tumor growth was monitored by
bioluminescence imaging for a period of six weeks (Fig. 6A).
Silencing of ADMR in both cancer cells and the tumor
microenvironment in combination resulted in a significant
reduction in tumor volume by 8860.4% (p,0.05) at the end of
six weeks when compared to its control. Analysis of the effects of
ADMR silencing on endothelial cells in vivo was done using CD31
staining on tissue sections from mice bearing DOPC nanoliposome
coupled siControl or siADMR. Silencing of ADMR resulted in
significant reduction in open blood vessels when compared to their
control tissues (Fig. 6B). We also analyzed the effects of silencing
ADMR on VEGF production on these sections. Silencing of
ADMR did not alter VEGF production (Fig. 6C).
Discussion
In the current study, we evaluated the role of AM receptors in
tumor cells and cells in the tumor microenvironment and
examined the effectiveness of inhibiting ADMR as a potential
therapeutic target. We previously reported that AM is over-
expressed in pancreatic cancer and stimulates cancer cells via an
autocrine loop resulting in increased tumor growth [3]. Other
studies have indicated that AM also promotes tumor growth by
stimulation of angiogenesis through effects on endothelial cells
within the tumor microenvironment [10]. Taken together, these
observations suggested that AM might be a useful target for cancer
Figure 3. Effect of ADMR on tumor growth in vivo. Orthotopic tumors were developed with MPanc96 (A) or BxPC3 (B) cells stably silenced with
shADMR and expressing the luciferase gene. After 4 weeks, the tumor volume was estimated by bioluminescence imaging and showed a significant
reduction between ADMR and shControl vector bearing tumors from both cell types. Data shown are means +/2 SEM for 10 animals per group.
(*p,0.05) Bioluminescence images of representative mice are also provided.
doi:10.1371/journal.pone.0007502.g003
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7502Figure 4. Effects of ADMR on metastasis. MPanc96 cells bearing luciferase gene stably transfected with shControl or shADMR cells were injected
into the tail vein to measure lung metastasis and into the spleen to measure liver metastasis. Animals bearing ADMR silenced cells showed reduction
in the incidence of lung (A) and liver metastases (B) as measured by bioluminescence imaging. After 6 weeks mice were sacrificed and lung and liver
were also excised and examined grossly and histologically. Stable silencing of ADMR reduced the number of metastatic foci on lung and liver when
compared to shControl. Representative pictures show the reduction in number of metastatic foci in lungs (C) and livers (D).
doi:10.1371/journal.pone.0007502.g004
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by its actions on at least two types of G-protein-coupled receptors,
CRLR [26] and ADMR [19]. For this reason, there is a concern
that systemic inhibition of AM may have significant and possibly
harmful effects on normal physiology. Therefore, rather than
targeting AM itself, we were interested in the possibility of
targeting one of its receptors. Currently little is known about the
relative contributions of ADMR or CRLR to the physiological or
pathophysiological actions of AM. In the current study, we found
that ADMR is the primary receptor responsible for the growth
stimulatory effects of AM on pancreatic cancer, HPSCs and
endothelial cells and that ADMR silencing by systemic delivery of
siRNA was feasible and effective against pancreatic cancer without
obvious detrimental effects to overall health.
In this study, we showed for the first time that both HPSC and
endothelial cells secreted AM, similar to what we previously
observed for cancer cells [3]. Also in this study, treatment with a
short peptide of AM, which acts as an antagonist, reduced basal
proliferation of each of these cell types. These data suggest the
presence of an autocrine loop. We also observed that exogenous
addition of AM stimulated the growth of each of these cell types
and stimulated in vitro angiogenesis in cultures of endothelial cells.
It has previously been reported that AM treatment stimulates
endothelial cell proliferation and in vitro angiogenesis [12,27]. It
has also previously been observed that AM is secreted by human
hepatic stellate cells, which are similar to pancreatic stellate cells,
and acts in an autocrine manner to regulate contractility of these
cells [28]. Therefore, AM is present and likely secreted by several
cell types that constitute the tumor microenvironment.
AM has two potential receptors, ADMR and CRLR. We were
interested to determine whether both receptors were important for
the ability of AM to stimulate pancreatic tumor growth or whether
one receptor might be more important. We previously observed
that pancreatic cancer cells express exclusively ADMR [3].
However, in that study we did not determine whether this
receptor was required for the effects of AM on the cancer cells.
Figure 5. Effect of ADMR silencing in tumor microenvironment cells in vivo. (A) MPanc96 cells were transfected with siControl or siADMR
and after 72 hours western blotting was conducted. SiADMR significantly reduced expression of ADMR on MPanc96 cells. The same blot was probed
for b-Actin, which served as loading control. (B) Athymic nude mice were treated with DOPC nanoliposome coupled siControl or siADMR (mouse)
(10 ug per animal i.p. twice a week for four weeks), then sacrificed and the pancreas was analyzed ADMR by RT-PCR using the mouse ADMR primers.
ADMR was almost completely silenced by siADMR treatments. 18S served as loading control. Full length gels are presented in Figure S2. (C) Body
weight of mice treated with DOPC nanoliposome coupled siControl or siADMR did not show any difference after a period of four weeks. (D) Glucose
tolerance test (GTT) was performed on these mice by injecting 1.5 mg glucose/g body weight i.p. Systemic silencing of ADMR did not affect glucose
levels when compared to DOPC nanoliposome coupled siControls.
doi:10.1371/journal.pone.0007502.g005
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on endothelial cells or stellate cells is unknown. It has been
reported that endothelial cells express CRLR [27] and it has been
suggested that CRLR is the main mediator of the effects of AM on
the vasculature [29]. Therefore, we examined the importance of
the different receptors by silencing them individually on each of
Figure 6. Effects of systemic delivery of DOPC nanoliposome coupled human and mouse siADMR in vivo. (A) In vivo targeting of ADMR
using DOPC nanoliposome coupled human and mouse siADMR in combination. SiRNAs were delivered (each 10 ug per animal i.p. twice a week) to
athymic nude mice bearing human pancreatic cancer cells (MPanc96 with luciferase gene) and monitored for a period of six weeks. These treatments
caused a significant reduction in tumor volume as measured by bioluminescence imaging. Representative pictures of mice show the
bioluminescence images of treated and untreated pancreatic cancer. (B) Tissues from orthotopic tumors developed with MPanc96 cells and treated
with siControl or siADMR (human and mouse in combination) were processed immunohistochemically for CD31 staining. SiControl treated cells
showed open blood vessels, while siADMR treated cells showed constricted or collapsed blood vessels. Shown are representative micrographs. (C)
Immunohistochemical staining of VEGF showed no differences between siControl or siADMR treated tumors.
doi:10.1371/journal.pone.0007502.g006
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proliferation of HPSC, HUVEC and MLEC cells in vitro while
silencing of CRLR had no effect. ADMR was also primarily
responsible for the angiogenic effects of AM on HUVECS and
MLECs, while CRLR had lesser effects. Previously it was reported
that an anti-CRLR antibody reduced the angiogenic functions of
AM on endothelial cells [27,30]. However, in that study they did
not evaluate the effects of ADMR. Our data clearly indicate the
primary importance of ADMR on pancreatic cancer cells and cells
resembling the stellate and endothelial cells found in the
pancreatic tumor microenvironment.
Having identified ADMR as a critical AM receptor for pancreatic
tumors, we tested the effect of silencing ADMR in vivo as a potential
approach to pancreatic cancer therapy. We first examined the effect
of silencing ADMR specifically in cancer cells by stably silencing
ADMR in human pancreatic cancer cells in vitro and then using
them to develop orthotopic tumors. We observed a dramatic
reduction on tumor volume after silencing ADMR in two different
pancreatic cancer cell lines. These dramatic effects emphasized the
importance of the ADMR receptor and the AM autocrine loop in
pancreatic cancer cells.
We also observed a reduction in metastasis after silencing ADMR.
However, because of the large effect of ADMR silencing on primary
tumor growth, it was difficult to determine if this involved more than
simply reduced cancer cell growth. To determine whether the
reduction in metastasis was independent of the reduced tumor
growth, we examined the behaviour of the ADMR silenced cells in
lung and liver metastasis studies. By injection of cancer cells into the
tail vein, the cells are carried to various organs but tend to form
colonies in the lung. Similarly, injection of cancer cells into the spleen
leads to the development of metastases in the liver. The number of
colonies formed in these assays does not depend on the growth rate of
the cells. Using sensitive bioluminescence imaging we observed a
highly significant reduction in the incidence of metastases as well
postponement on the presence of detectable metastases in both lung
and liver using ADMR silenced cells. Reduction in number of lung
and liver metastatic foci were also seen on silencing ADMR in vivo.
These studies supported AM as a metastatic factor apart from also
being a growth inducer and potent angiogenic factor.
To develop the idea of targeting ADMR therapeutically, we
investigated the effects of systemic delivery of siRNA using
liposomes. Initially we were concerned that the silencing of this
receptor might prove deleterious. Previously it was reported that
CRLR knock-out mice were embryonically lethal [31]. However,
when we silenced ADMR by systemic delivery of DOPC
nanoliposome coupled siRNA to mouse ADMR we did not
observe any effects on body weight, feeding behavior, activity or
blood glucose levels of the animals, despite highly effective
silencing of ADMR in the pancreas. Thus, tentatively it appears
that systemic ADMR silencing is not overtly harmful. Clearly, full
toxicology studies will be required before moving this treatment
forward to human trials. Notably, unlike typical siRNA studies, in
the current study ADMR was silenced on both the cancer cells and
systemically by using siRNAs of both human and mouse ADMR.
Silencing of only the human form does not test the systemic effects
of siRNA treatment as would occur if this treatment was translated
to the clinic. We observed that treatment of the mice with the
combination of both human and mouse siRNA to ADMR greatly
inhibited tumor growth and angiogenesis in vivo without obvious
harmful effects.
The reduction of angiogenesis associated with ADMR silencing
was not associated with a reduction in VEGF production. This is
in keeping with previous observations suggesting that AM does not
act through VEGF stimulation in the process of angiogenesis. It
was previously shown that down regulation of VEGF or its
receptor, VEGFR-2, could not suppress AM induced angiogenesis
[30]. Interestingly, an AM antagonist was able to inhibit VEGF
induced blood flow [32]. Our data suggests that AM acts as an
VEGF-independent angiogenic factor and a reduction in AM’s
function in cancer cells and the adjacent tumor microenvironment
cells results in reduced neoangiogenesis.
Thus, this study collectively delineated the autocrine effects of
AM in pancreatic cancer and identified ADMR as the critical
receptor through which these effects are mediated on both tumor
cells and cells within the tumor microenvironment. Because the
effects of ADMR silencing on pancreatic cancer cells were so
dramatic, we expect that this is the major site of action of the in vivo
silencing experiments. Importantly, we showed that silencing
ADMR in vivo greatly reduced tumor growth without overt
deleterious effects. These data generally support the suggestion
that ADMR may be a potent therapeutic target in pancreatic
cancer.
Supporting Information
Figure S1 Silencing of ADMR or CRLR on HPSCs, HUVECs,
or MLECs. (A) HPSC and (B) HUVEC cells were silenced with
respective human siRNAs (5nM) for 72 hours. Western blotting
was conducted for either ADMR or CRLR using human
antibodies and the same blots were probed for b-Actin, which
served as loading control. (C) MLEC cells were transfected with
mouse siRNAs against ADMR and CRLR and after 72 hours
total RNA was isolated and RT-PCR was conducted with
respective mouse primers and with 18S, which served as loading
control.
Found at: doi:10.1371/journal.pone.0007502.s001 (0.73 MB TIF)
Figure S2 Western blot of MPanc96 cells showing the silencing
effect of siADMR. MPanc96 cells transfected with siRNAs (5nM)
(siControl, siADMR or siCRLR) showed a significant silencing of
ADMR after 72 hours. The same blot was probed for b-Actin
which served as loading control (In vitro silencing). Athymic nude
were treated with DOPC nanoliposomes coupled with siControl or
siADMR (mouse) (10 ug per animal i.p. twice a week for four
weeks) and were sacrificed and the level of endogenous ADMR
was evaluated. RT-PCR using mouse ADMR primers showed the
complete silencing of ADMR after delivery of DOPC nanolipo-
some coupled mouse siADMR as compared to siControl delivered
animals. 18S served as loading control (In vivo silencing).
Found at: doi:10.1371/journal.pone.0007502.s002 (0.24 MB TIF)
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